lhfpl3 Antibody

What is LHFPL3 and why is it relevant to scientific research?

LHFPL3 (Lipoma HMGIC Fusion Partner-Like 3) is a member of the LHFP protein family and belongs to the superfamily of tetraspan transmembrane protein encoding genes. In humans, the canonical protein has a reported length of 236 amino acid residues and a mass of 25.8 kDa, with its subcellular localization primarily in the membrane . The protein has gained research significance due to its involvement in several pathological processes, particularly in cancer biology. LHFPL3 has been implicated in glioblastoma progression and melanoma development , making it an important target for understanding disease mechanisms and potential therapeutic approaches.

Gene orthologs of LHFPL3 have been identified across multiple species including mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken, indicating evolutionary conservation and biological importance . The protein is often referred to by several synonyms including LHFP-like protein 3, lipoma HMGIC fusion partner-like 3 protein, and occasionally as LHFPL4, though the latter may cause confusion with the distinct LHFPL4 gene.

• Cancer tissues: LHFPL3 shows significant upregulation in melanoma tissues compared to adjacent normal tissues, with higher expression correlating with poorer survival outcomes . According to GEPIA database analysis, patients with high LHFPL3 expression levels have shorter survival rates compared to those with low expression .

• Glioblastoma: LHFPL3 is highly expressed in malignant glioma cells and plays a role in cell proliferation, migration, and invasion .

• Inflammatory conditions: In contrast to cancer contexts, the antisense RNA LHFPL3-AS2 shows reduced expression in Crohn's disease ileum samples, with further reduction correlating with disease severity .

When interpreting expression data, researchers should consider both protein and transcript levels, as post-transcriptional regulation may result in discrepancies between mRNA and protein expression patterns. Additionally, subcellular localization analysis reveals that LHFPL3 RNA is expressed in both nuclear and cytoplasmic compartments, suggesting complex functional roles .

How should researchers validate the specificity of LHFPL3 antibodies?

Proper validation of LHFPL3 antibodies is essential to ensure experimental reliability. A comprehensive validation strategy should include:

• Western blot analysis: LHFPL3 antibodies should detect a specific band around 25.8 kDa (the predicted molecular weight of human LHFPL3). Validation should include positive controls (tissues/cells known to express LHFPL3) and negative controls.

• Knockdown/knockout verification: Expression should be significantly reduced in samples where LHFPL3 has been silenced using siRNA, shRNA, or CRISPR-Cas9 approaches. As demonstrated in melanoma stem cell research, LHFPL3 expression can be effectively knocked down using lentivirus-mediated shRNA targeting both long (1334 bp) and short (973 bp) isoforms .

• Immunofluorescence specificity: For immunofluorescence applications, specificity can be confirmed by comparing staining patterns in cells transfected with miR-218-5p mimics (which reduce LHFPL3 expression) versus control plasmids. Reduced LHFPL3 staining density in treated cells confirms antibody specificity, as demonstrated in U87 and U251 glioma cell lines .

• Cross-reactivity assessment: Test the antibody against related proteins (e.g., other LHFPL family members) to ensure minimal cross-reactivity.

• Peptide competition: Pre-incubation of the antibody with the immunizing peptide should abolish the specific signal.

What are the optimal protocols for immunofluorescence detection of LHFPL3?

For optimal immunofluorescence detection of LHFPL3, researchers should follow these methodological guidelines based on published protocols:

• Cell preparation: Culture cells (e.g., U87 and U251 cell lines) on appropriate coverslips or chamber slides and allow them to reach desired confluence (typically 60-80%).

• Fixation and permeabilization:

  • Fix cells in 4% paraformaldehyde for 15-20 minutes at room temperature

  • Permeabilize in ice-cold methanol for 10 minutes

  • Block with 1% BSA solution for 30-60 minutes to reduce non-specific binding

• Primary antibody incubation:

  • Use LHFPL3 antibody at an optimized dilution (typically 1:50 to 1:100)

  • Incubate overnight at 4°C or for 1-2 hours at room temperature

  • Include cytoskeletal markers (e.g., actin at 1:400 dilution) for co-localization studies

• Secondary antibody incubation:

  • Use appropriate species-specific secondary antibodies (anti-rabbit IgG at 1:1000 dilution)

  • Include nuclear counterstain (e.g., Hoechst 33342)

  • Incubate for 1 hour at room temperature protected from light

• Visualization:

  • Mount slides with appropriate anti-fade mounting medium

  • Image using fluorescence microscopy (e.g., Nikon Eclipse Ti-U fluorescence microscope equipped with digital camera)

This protocol has been successfully employed to visualize LHFPL3 expression changes following miR-218-5p transfection in glioma cell lines, demonstrating reduced staining density in treated compared to control cells .

What controls should be included when performing Western blot analysis for LHFPL3?

When performing Western blot analysis for LHFPL3, inclusion of appropriate controls is critical for result interpretation and validation:

• Positive control: Include lysates from cells or tissues known to express LHFPL3 (e.g., glioma cell lines U87 and U251, or melanoma stem cells).

• Negative control: Include lysates from cells with confirmed low or no LHFPL3 expression, or cells where LHFPL3 has been knocked down using siRNA or shRNA.

• Loading control: Include detection of housekeeping proteins (e.g., β-actin, GAPDH, or α-tubulin) to ensure equal loading across samples and to normalize LHFPL3 expression.

• Molecular weight marker: Include a protein ladder to confirm the expected molecular weight of LHFPL3 (approximately 25.8 kDa).

• Treatment controls: When examining the effects of miRNAs or other regulators on LHFPL3 expression, include appropriate negative control mimics or scrambled sequences to distinguish specific from non-specific effects.

For instance, in glioma research, Western blot analysis confirmed decreased LHFPL3 expression following miR-218-5p transfection compared to negative control treatments, providing evidence for direct regulation of LHFPL3 by this miRNA .

How can LHFPL3 antibodies be utilized to investigate miRNA-mediated regulation of LHFPL3?

LHFPL3 antibodies play a crucial role in investigating miRNA-mediated regulation of this protein in various disease contexts. Research has established that LHFPL3 is directly targeted by miR-218-5p, with important implications for cancer progression. Here's a methodological approach for using LHFPL3 antibodies to study this regulation:

• Luciferase reporter assays: First establish direct binding between miRNA and LHFPL3 using luciferase reporter constructs containing wild-type or mutated LHFPL3 3'-UTR sequences. In glioblastoma research, cells transfected with psiCHECK-2-LHFPL-3'UTR-WT showed significantly reduced luciferase activity when co-transfected with miR-218-5p compared to negative controls or mutated constructs .

• Transfection experiments:

  • Transfect cells with miRNA mimics (e.g., miR-218-5p) or inhibitors

  • Include appropriate negative controls (scrambled sequences)

  • Harvest cells 24-48 hours post-transfection

• Protein expression analysis:

  • Use LHFPL3 antibodies in Western blot to quantify changes in protein expression

  • Normalize to loading controls (β-actin, GAPDH)

  • Compare expression levels between miRNA-treated and control cells

• Immunofluorescence visualization:

  • Apply LHFPL3 antibodies in immunofluorescence to visualize expression changes and subcellular localization

  • Co-stain with cytoskeletal markers for localization context

  • Quantify fluorescence intensity to measure expression differences

This methodological approach has successfully demonstrated that miR-218-5p significantly reduces LHFPL3 expression in glioma cells, with functional consequences for cell proliferation, migration, and epithelial-mesenchymal transition (EMT) .

What is the role of LHFPL3 in cancer progression and how can antibodies help elucidate its functions?

LHFPL3 has emerged as an important player in cancer progression, particularly in melanoma and glioblastoma. LHFPL3 antibodies serve as critical tools for investigating its complex roles in these contexts:

• Expression correlation with clinical outcomes: Immunohistochemical analysis using LHFPL3 antibodies in patient samples has revealed that high LHFPL3 expression correlates with poor prognosis in melanoma patients. Kaplan-Meier survival analysis shows significantly shorter survival rates in patients with high LHFPL3 expression compared to those with low expression .

• Functional characterization through knockdown studies: By combining LHFPL3 antibodies with knockdown approaches, researchers have revealed that:

  • In melanoma stem cells, LHFPL3 silencing leads to decreased cell proliferation, cell cycle arrest in G0/G1 phase, and increased apoptosis

  • In glioma cells, suppression of LHFPL3 (through miR-218-5p upregulation) inhibits cell activity, proliferation, and invasive ability

• Mechanistic pathway analysis: Using LHFPL3 antibodies in combination with other pathway-specific antibodies, researchers have uncovered that:

  • LHFPL3-AS1 (the antisense lncRNA) forms a positive feedback loop with STAT3, promoting melanoma progression through the JAK2/STAT3 signaling pathway

  • LHFPL3-long interacts with the PTBP1 protein, as demonstrated through RNA pull-down assays and confirmed by Western blotting with anti-PTBP1 antibody

• Therapeutic target assessment: Antibody-based detection methods help evaluate the potential of LHFPL3 as a therapeutic target by:

  • Measuring expression changes following treatment with potential therapeutic agents

  • Assessing downstream effects on proliferation, invasion, and EMT markers

  • Identifying patient populations most likely to benefit from LHFPL3-targeted therapies based on expression patterns

These findings collectively position LHFPL3 as a potential biomarker and therapeutic target in cancer research, with antibodies serving as essential tools for further mechanistic investigations.

How does the antisense RNA LHFPL3-AS2 function in epithelial homeostasis and how can this be studied?

The antisense RNA LHFPL3-AS2 plays a critical role in maintaining epithelial homeostasis, with implications for inflammatory conditions like Crohn's disease. Research methodologies using antibodies to study this function include:

• Expression profiling in disease states: RNA sequencing has identified reduced LHFPL3-AS2 expression in treatment-naïve Crohn's disease ileum samples, with further reduction correlating with disease severity and ileal ulceration .

• Functional characterization through knockdown models: LHFPL3-AS2 knockdown in Caco-2 cells has revealed profound effects on epithelial morphology and function:

  • Reduced epithelial monolayer confluency and spreading

  • Atypical cell rounding and clumping

  • Impaired 3D cyst formation with defective internal lumen development

  • Mislocalization of actin and junction proteins (adherent and tight junctions)

• Pathway analysis using antibody-based techniques: Antibodies against junction proteins, cytoskeletal components, and polarity markers help elucidate the mechanisms through which LHFPL3-AS2 regulates epithelial homeostasis:

  • Immunofluorescence staining of actin and junction proteins reveals polarization defects

  • Antibodies against mitotic spindle components demonstrate defective spindle formation

  • Western blot analysis of epithelial polarity markers shows altered expression following LHFPL3-AS2 knockdown

• Transcriptomic impact assessment: mRNA-seq analysis of LHFPL3-AS2 knockdown cells highlights:

  • Reduction of genes involved in apical polarity

  • Downregulation of actin bundle formation pathways

  • Altered morphogenesis pathways

  • Disruption of the β-catenin-TCF4 complex

These findings establish LHFPL3-AS2 as a critical regulator of epithelial morphogenesis, polarity, mitotic spindle formation, and proliferation—key processes for maintaining epithelial homeostasis that are disrupted in inflammatory conditions like Crohn's disease.

What are common challenges in LHFPL3 antibody-based experiments and how can they be addressed?

Researchers working with LHFPL3 antibodies may encounter several technical challenges. Here are common issues and recommended solutions:

• Specificity concerns:

  • Problem: Non-specific binding or cross-reactivity with other LHFP family proteins

  • Solution: Use antibodies targeting the C-terminal region of LHFPL3, which shows greater sequence divergence from other family members. Multiple commercial antibodies specifically target this region . Always include appropriate controls and validation steps as outlined in question 2.1.

• Signal detection issues:

  • Problem: Weak or absent signal in Western blot or immunofluorescence

  • Solution: Optimize antibody concentration (typically 1:50 to 1:400 for immunofluorescence, 1:500 to 1:2000 for Western blot). Consider extended incubation times (overnight at 4°C) and enhanced detection systems. For Western blot, ensure sufficient protein loading (30-50 μg total protein).

• Isoform detection challenges:

  • Problem: LHFPL3 has multiple isoforms (long variant: 1334 bp; short variant: 973 bp)

  • Solution: Select antibodies that recognize common epitopes present in all isoforms. For isoform-specific detection, choose antibodies targeting unique regions or use RNA-based methods alongside protein detection.

• Subcellular localization variability:

  • Problem: LHFPL3 is present in both nuclear and cytoplasmic compartments, complicating localization studies

  • Solution: Use cell fractionation followed by Western blot to quantify distribution, complemented by high-resolution confocal microscopy with appropriate subcellular markers.

• Expression level variations:

  • Problem: Expression levels vary greatly between cell types and disease states

  • Solution: Include appropriate positive controls known to express LHFPL3 (e.g., melanoma stem cells, glioblastoma cell lines). Adjust exposure times or detection sensitivity accordingly, and always normalize to stable reference genes/proteins.

How should researchers interpret contradictory findings between LHFPL3 protein and RNA expression data?

Discrepancies between protein and RNA expression levels of LHFPL3 are not uncommon and require careful interpretation:

• Post-transcriptional regulation mechanisms:

  • miRNA-mediated regulation: miR-218-5p directly targets LHFPL3 mRNA, reducing protein expression without necessarily affecting transcript levels initially

  • RNA stability factors: LHFPL3 mRNA stability may be regulated by RNA-binding proteins, affecting the correlation between transcript and protein levels

  • Translation efficiency: Variations in translation efficiency may lead to different protein amounts despite similar mRNA levels

• Technical considerations:

  • Antibody specificity: Ensure the antibody detects all relevant isoforms of LHFPL3 protein

  • RNA probe design: Confirm that qPCR primers or RNA-seq analysis captures all transcript variants

  • Sample preparation: Differences in protein extraction efficiency versus RNA isolation may contribute to apparent discrepancies

• Analytical approach for reconciling differences:

  • Temporal analysis: Examine both RNA and protein levels at multiple time points to detect delayed effects

  • Isoform-specific analysis: Determine if discrepancies are isoform-specific by using primers/antibodies targeting specific variants

  • Subcellular compartmentalization: Assess whether protein localization changes while total expression remains stable

• Biological significance assessment:

  • Functional studies: Determine which measurement (RNA or protein) better correlates with biological function

  • Disease relevance: In melanoma, protein expression levels show stronger correlation with patient outcomes than transcript levels in some cases

  • Regulatory network context: Consider the broader regulatory network; in some contexts, antisense RNAs like LHFPL3-AS1/2 may affect protein function without altering expression levels

Understanding these complex relationships helps researchers correctly interpret experimental findings and place them in the appropriate biological context.

What are the best practices for using LHFPL3 antibodies in co-immunoprecipitation experiments?

When using LHFPL3 antibodies for co-immunoprecipitation (co-IP) experiments to identify protein interaction partners, researchers should follow these best practices:

• Antibody selection criteria:

  • Choose antibodies specifically validated for immunoprecipitation applications

  • Select antibodies that recognize native (non-denatured) epitopes

  • Consider using tag-based approaches (expressing tagged LHFPL3) if direct IP is challenging

• Optimization of lysis conditions:

  • Use mild, non-denaturing lysis buffers to preserve protein-protein interactions

  • Test different detergent concentrations (e.g., 0.5-1% NP-40 or Triton X-100)

  • Include protease and phosphatase inhibitors to prevent degradation during processing

• Critical controls:

  • Input control: Reserve 5-10% of lysate pre-IP as an input control

  • Negative control: Perform parallel IP with isotype-matched IgG

  • Specificity control: When possible, conduct IP in cells with LHFPL3 knockdown

  • Reciprocal IP: Confirm interactions by IP of the suspected binding partner

• Crosslinking considerations:

  • For transient or weak interactions, consider using crosslinking reagents

  • For RNA-protein interactions involving LHFPL3, crosslinking and immunoprecipitation (CLIP) assays have been successfully employed

• Detection methods:

  • Western blot: Use specific antibodies against suspected interaction partners

  • Mass spectrometry: For unbiased identification of novel interaction partners

  • RNA analysis: For RNA-protein complexes, extract and analyze RNA from immunoprecipitates

These approaches have been successfully employed to identify protein interactions relevant to LHFPL3 function. For example, RNA pull-down and CLIP assays revealed that LHFPL3-AS1-long interacts with the PTBP1 protein, with the interaction specifically mapping to a 250-bp fragment (nucleotides 1050-1330) containing known PTBP1 binding sites (UCUU and UCUCU) .

How can LHFPL3 antibodies be utilized in examining the role of LHFPL3 in developmental processes?

While current research primarily focuses on LHFPL3's role in disease states, LHFPL3 antibodies can be valuable tools for investigating developmental functions across multiple model systems:

• Developmental expression profiling:

  • Utilize LHFPL3 antibodies in immunohistochemistry or immunofluorescence to map expression patterns during embryonic and post-natal development

  • Compare expression across multiple species (mouse, rat, zebrafish) given the conservation of LHFPL3 across vertebrates

  • Correlate protein expression with known developmental milestones to identify potential functional relevance

• Lineage tracing and fate mapping:

  • Combine LHFPL3 antibody staining with lineage-specific markers to identify cell populations expressing LHFPL3 during development

  • Track changes in expression as cells differentiate and mature

  • Examine potential roles in stem cell maintenance and differentiation, building on findings from cancer stem cell models

• Conditional knockout models:

  • Use LHFPL3 antibodies to validate tissue-specific or temporally controlled LHFPL3 knockout efficiency

  • Assess morphological and functional consequences of LHFPL3 loss during specific developmental windows

  • Examine potential compensatory mechanisms through expression analysis of related family members

• Organ/tissue-specific developmental roles:

  • Given LHFPL3's role in epithelial organization and polarity , investigate its function in organs requiring complex epithelial structures

  • Examine potential neural developmental roles, building on expression in neural tissues and functions identified in glioblastoma

  • Assess vascular development implications, considering links to VEGF regulation pathways

These approaches would significantly expand our understanding of LHFPL3's physiological functions beyond its currently characterized roles in pathological states.

What novel therapeutic approaches might target LHFPL3, and how can antibodies support this research?

LHFPL3's involvement in cancer progression makes it a potential therapeutic target. Antibodies can support development of novel therapeutic approaches in several ways:

• Target validation and patient stratification:

  • Use LHFPL3 antibodies in tissue microarrays to identify patient populations with high expression

  • Correlate expression levels with treatment response and survival outcomes

  • Develop diagnostic antibodies that could identify patients most likely to benefit from LHFPL3-targeted therapies

• Therapeutic mechanism exploration:

  • miRNA-based approaches: Building on established miR-218-5p regulation of LHFPL3 , antibodies can help validate the efficiency of miRNA delivery systems by measuring resulting protein reduction

  • Antisense oligonucleotide approaches: Antibodies can assess the effectiveness of antisense oligonucleotides designed to reduce LHFPL3 expression

  • Small molecule inhibitors: For protein-protein interactions involving LHFPL3, antibodies can help screen compounds that disrupt these interactions

• Combination therapy assessment:

  • Use LHFPL3 antibodies to monitor expression changes during standard treatments

  • Identify synergistic approaches where conventional therapies combined with LHFPL3 targeting show enhanced efficacy

  • Evaluate whether LHFPL3 expression correlates with resistance to existing therapies

• Functional consequences monitoring:

  • Assess downstream effects of LHFPL3 inhibition on:

    • JAK2/STAT3 signaling pathway activation

    • EMT marker expression changes

    • Bcl-2 expression and apoptotic response

    • Cell cycle progression and proliferation markers

• Potential antibody-drug conjugates:

  • Evaluate membrane localization of LHFPL3 for potential antibody-drug conjugate approaches

  • Assess internalization efficiency of LHFPL3 antibodies in cancer cell models

  • Develop modified antibodies with enhanced tumor penetration properties

These research directions could significantly advance therapeutic development targeting LHFPL3 in cancer and potentially other diseases where its expression is dysregulated.

How might single-cell analysis techniques incorporating LHFPL3 antibodies advance our understanding of heterogeneous diseases?

Single-cell analysis incorporating LHFPL3 antibodies offers powerful approaches to understand cellular heterogeneity in complex diseases:

• Single-cell protein profiling:

  • Mass cytometry (CyTOF) incorporating LHFPL3 antibodies can reveal co-expression patterns with other markers across thousands of individual cells

  • Imaging mass cytometry combines LHFPL3 detection with spatial information in tissue contexts

  • Antibody-based microfluidic approaches can quantify LHFPL3 expression in rare cell populations

• Integrated multi-omics approaches:

  • CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing) combining LHFPL3 antibodies with transcriptome analysis can reveal:

    • Correlations between LHFPL3 protein levels and gene expression programs

    • Identification of cellular states where LHFPL3 is functionally active

    • Potential compensatory mechanisms in cells with varying LHFPL3 expression

• Disease heterogeneity mapping:

  • In tumors like melanoma and glioblastoma, where LHFPL3 expression is elevated , single-cell approaches can:

    • Identify specific tumor cell subpopulations with highest LHFPL3 expression

    • Correlate expression with stemness markers in cancer stem cell populations

    • Map spatial distribution of LHFPL3-expressing cells relative to microenvironmental features

• Trajectory analysis:

  • Combined with other markers, LHFPL3 antibodies can help track cellular state transitions during:

    • Disease progression from early to advanced stages

    • Treatment response and resistance development

    • EMT processes where LHFPL3 has established functional roles

• Clinical applications:

  • Development of companion diagnostics for targeted therapies

  • Identification of minimal residual disease based on LHFPL3-expressing cells

  • Prediction of disease recurrence patterns based on persisting LHFPL3-high cell populations

These approaches would significantly advance our understanding of the heterogeneous roles LHFPL3 plays across different cell populations within complex disease tissues, potentially revealing new therapeutic opportunities and improving patient stratification for precision medicine approaches.